An observational study in Ischemic Stroke, Chronic Disease and Cardiovascular, sponsored by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital. Recruiting at 1 site in China. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.
Among the 754 studies in Ischemic Stroke with a site in China, this one is the 24th largest by planned enrollment of the 188 observational ones that give a count, is one of 125 that started in 2026, is one of 188 observational ones, reaches primary completion later than 398 of the 399 other live ones, and was the 687th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:
Xidian University · Sites in China
Ages 18+
The First Affiliated Hospital of Zhengzhou University · Sites in China
Ages 18+
Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Sites in China
Ages 18–85
Yongjun Wang · Sites in China
Ages 18+
Shandong Provincial Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
754 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 110 · Phase 3 136 · Phase 4 70
First in 2000; this study’s year is marked. 125 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 271 across the 566 interventional studies, 625 across the 188 observational. Of the 235 that completed or were terminated, 11 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 754 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital as lead sponsor.
The Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central Hospital has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
108 of the studies in Ischemic Stroke with a site in China that are under way reach primary completion within a year, 22 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559241Phase 3Capital Medical UniversityRemote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy(RECAST-MT) | 2026-11 |
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
| NCT06749834Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityIntravenous Thrombolysis and NOAC | 2026-12-31 |
| NCT07335107Phase 3Beijing Tiantan HospitalIntravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion | 2027-01-31 |
| NCT06954155Phase 3Beijing Tiantan HospitalTenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND | 2027-02-28 |
Add all 108 to your calendar (.ics) → With an account.
Among the 754 studies in Ischemic Stroke with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project will establish a cohort related to stroke and tumors, with 4500 subjects selected from the 30-80-year-old urban-rural integrated population in Lishui City, covering both urban and rural residents in the urban-rural junction area of the region. This population, with diverse living habits and uneven access to medical resources, is a key group for the prevention and control of stroke and tumors, and its selection can reflect the epidemiological characteristics of the two diseases in Lishui.
To achieve the research goal, the subjects will be randomly divided into three groups for targeted detection, with specific schemes as follows:
Group A: Magnetic Resonance (MR) examination (focusing on the head and neck to identify cerebrovascular and tissue abnormalities) and methylation pan-cancer detection (non-invasive and high-sensitivity, used to screen for early methylation abnormal changes of tumor-related genes).
Group B: Methylation pan-cancer detection (consistent with Group A), Transcranial Doppler (TCD) examination (for intracranial hemodynamic monitoring), cervical ultrasound (for assessing cervical artery conditions), and Vibration-Controlled Transient Elastography (VCTE) examination (for detecting liver elasticity).
Group C: Physiological age methylation detection (evaluating the real physiological aging state through the methylation level of age-related CpG sites) and VCTE examination (consistent with Group B) to supplement liver function-related detection.
The core purpose of this project is to explore the three-dimensional distribution (time, place, and population distribution) of stroke and tumors in this population. Time distribution aims to explore the variation rules of incidence rates across different seasons, years, and age stages; regional distribution aims to analyze the differences in incidence rates among different urban-rural junctions and their correlation with environmental and medical resource factors; population distribution aims to identify high-risk groups by analyzing the differences in incidence rates among different genders, ages, living habits, and physiological aging states.
In addition, this project will clarify the correlation between each detection indicator and the two diseases, improve the construction of biological sample banks and databases, provide a scientific basis for establishing a community-hospital linked intervention system, thereby improving the early detection rate and intervention rate of diseases and protecting the health of residents
The study population consists of 4,500 participants aged 30-80 years recruited from 10 urban and 10 rural sites in Lishui City using a cluster sampling method. Participants are randomly divided into three equal groups of 1,500 each, receiving different examination protocols. The collected data are further analyzed and grouped into cerebrovascular, tumor, and epigenetic age categories based on the respective test results.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the cerebrovascular group receive head and neck magnetic resonance (MR) examination, transcranial Doppler (TCD) and cervical ultrasound. These examinations are used to screen cerebrovascular structural lesions, intracranial hemodynamic disorders and cervical atherosclerotic plaques, so as to identify early risk factors for stroke and cerebrovascular diseases.
The tumor group undergoes methylation pan-cancer detection. This non-invasive and high-sensitivity assay is applied to screen aberrant methylation of tumor-related genes, covering ten common cancers including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer and pancreatic cancer, enabling early identification of potential malignant tumor risk in the population.
The epigenetic age group accepts physiological age methylation detection combined with Vibration-Controlled Transient Elastography (VCTE). Methylation profiling of age-related CpG sites is used to evaluate individual physiological aging status, while VCTE is supplemented to assess liver elasticity and related metabolic characteristics.
Prevalence rate of stroke and tumors
A blood-based methylation pan-cancer assay was performed to screen for ten common malignancies, including cervical cancer, esophageal cancer, lung squamous cell carcinoma, prostate cancer, liver cancer, lung adenocarcinoma, colon cancer, rectal cancer, gastric cancer, and pancreatic cancer. The prevalence of each cancer type was calculated as the number of confirmed positive cases divided by the total number of participants screened.
Time frame: From enrollment to the end of the 10-year follow-up period
Unilateral carotid artery stenosis rate
The degree of cervical vascular stenosis was detected and evaluated. The distribution of unilateral carotid artery stenosis rate (defined as stenosis degree \>50%) was analyzed, which was calculated as the number of participants with carotid stenosis greater than 50% divided by the total screened population.
Time frame: From enrollment to the end of the 10-year follow-up period
Plan to share: No — The individual participant data (IPD) for this study will not be shared publicly due to concerns regarding participant privacy, data security, and the lack of an established data sharing agreement and platform. All data are stored and managed in accordance with applicable data protection regulations and institutional policies.
Start is estimated for May 2026; primary completion for May 2036, 120 months later.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 120 months is above that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.